GlycoMimetics Inc.

0.19
0.00 (2.65%)
At close: Apr 04, 2025, 10:12 AM
2.65%
Bid 0.19
Market Cap 12.1M
Revenue (ttm) n/a
Net Income (ttm) n/a
EPS (ttm) -0.59
PE Ratio (ttm) -0.32
Forward PE -2.8
Analyst n/a
Ask 0.19
Volume 60,957
Avg. Volume (20D) 1,380,685
Open 0.18
Previous Close 0.19
Day's Range 0.18 - 0.19
52-Week Range 0.14 - 2.83
Beta 1.81

About GLYC

GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing G...

Industry Biotechnology
Sector Healthcare
IPO Date Jan 10, 2014
Employees 4
Stock Exchange NASDAQ
Ticker Symbol GLYC
Full Company Profile
5 months ago
+191.32%
GlycoMimetics shares are trading higher after the ... Unlock content with Pro Subscription
9 months ago
+25.28%
GlycoMimetics shares are trading higher after the company disclosed that Chief Medical Officer Edwin Rock bought 305,000 shares at an average price of $0.26 per share.